Zura Bio (NASDAQ:ZURA) Stock Price Expected to Rise, Chardan Capital Analyst Says

Zura Bio (NASDAQ:ZURA) had its target price increased by investment analysts at Chardan Capital from $10.00 to $11.00 in a research note issued to investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Chardan Capital’s target price would suggest a potential upside of 100.00% from the stock’s current price.

ZURA has been the topic of several other reports. Leerink Partners raised Zura Bio to a “strong-buy” rating in a report on Sunday, November 23rd. Wedbush assumed coverage on shares of Zura Bio in a research report on Monday, February 9th. They issued an “outperform” rating and a $15.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a research note on Friday, January 9th. Finally, Oppenheimer lowered their price objective on shares of Zura Bio from $16.00 to $15.00 and set an “outperform” rating for the company in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $11.60.

Zura Bio Stock Down 10.1%

Shares of ZURA stock opened at $5.50 on Monday. The company’s fifty day simple moving average is $6.17 and its two-hundred day simple moving average is $4.57. Zura Bio has a 52 week low of $0.97 and a 52 week high of $7.44. The stock has a market cap of $357.61 million, a P/E ratio of -5.19 and a beta of 0.18.

Zura Bio (NASDAQ:ZURA) last issued its earnings results on Thursday, March 19th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.31). On average, analysts anticipate that Zura Bio will post -0.65 EPS for the current fiscal year.

Insider Buying and Selling at Zura Bio

In related news, major shareholder Ai Biotechnology Llc bought 2,000,000 shares of the business’s stock in a transaction dated Thursday, February 26th. The shares were purchased at an average price of $6.25 per share, with a total value of $12,500,000.00. Following the transaction, the insider owned 6,552,725 shares in the company, valued at $40,954,531.25. This trade represents a 43.93% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 22.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of ZURA. Allworth Financial LP bought a new position in Zura Bio during the fourth quarter valued at $30,000. Scientech Research LLC bought a new stake in shares of Zura Bio in the 3rd quarter worth about $45,000. Forefront Wealth Partners LLC purchased a new position in shares of Zura Bio during the 3rd quarter worth about $93,000. Dimensional Fund Advisors LP purchased a new position in shares of Zura Bio during the 4th quarter worth about $123,000. Finally, Squarepoint Ops LLC bought a new position in Zura Bio during the 3rd quarter valued at about $109,000. 61.14% of the stock is owned by hedge funds and other institutional investors.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.